Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease

Clinical Pharmacokinetics

Volumn 41, Issue 4, 2002, Pages 261-309

  Deleu, Dirk ^a   Northway, Margaret G ^a   Hanssens, Yolande ^b  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; ADRENERGIC RECEPTOR STIMULATING AGENT; AMANTADINE; AMITRIPTYLINE; ANTIHISTAMINIC AGENT; APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; BUTYROPHENONE DERIVATIVE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DECARBOXYLASE INHIBITOR; DIPHENHYDRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; HYDROCHLOROTHIAZIDE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PERGOLIDE; PHENOTHIAZINE DERIVATIVE; PRAMIPEXOLE; SELEGILINE; TOLCAPONE; TRIAMTERENE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMETHOPRIM; UNINDEXED DRUG;

BLOOD BRAIN BARRIER; CLINICAL PATHWAY; CONCENTRATION RESPONSE; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSPORT; HUMAN; KIDNEY CLEARANCE; LIVER BLOOD FLOW; MONOTHERAPY; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; MUSCARINIC ANTAGONISTS; PARKINSON DISEASE;

EID: 0036093898     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241040-00003     Document Type: Review

References (303)

1. De l'apomorphine dans certains troubles nerveux
2. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen der extrapyramidalen systems
3. Aromatic amino acids and modification of parkinsonism
4. Increase in cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase
5. Current and emerging strategies in the management of Parkinson's disease: A critical reappraisal
6. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines
7. Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption
8. Simultaneous determination of levodopa, its metabolites and carbidopa in clinical samples
9. Simultaneous monitoring of levodopa, dopamine and their metabolites in skeletal muscle and subcutaneous tissue in different pharmacological conditions using microdialysis
10. The use of capillary gas chromatography/mass spectrometry for the determination of acidic dopamine metabolites in human brain
11. Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection
12. Aromatic L-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with L-DOPA and L-5-hydroxytryptophan as substrates
13. Regulation of tryptophan and tyrosine hydroxylase
14. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines
15. Catechol-O-methytransferase and aromatic L-amino acid decarboxylase activities in human gastrointestinal tissues
16. Monoamine oxidase A and B from human liver and brain
17. Commentary: Monoamine oxidase, brain aging and degenerative disease
18. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: Localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain
19. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease
20. Clinical significance of the relationship between O-methyldopa levels and levodopa intake
21. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naïve and MPTP parkinsonian monkeys
22. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition
23. Temporal relationship between plasma and cerebrospinal fluid pharmacokinetics and clinical effect in Parkinson's disease
24. Metabolism of 3,4-dihydroxyphenylalanine (L-dopa) in human subjects
25. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: A comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers
26. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa
27. Clinical pharmacokinetics of anti-parkinsonian drugs
28. Clinical pharmacokinetics of amantadine hydrochloride
29. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function
30. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism
31. Active transport of L-dopa in the intestine
32. The influence of levodopa on gastric emptying in man
33. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease
34. Systemic activity of orally administered L-dopa in the elderly Parkinson patient
35. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in Parkinsonian patients
36. Antiparkinsonian agents: Drug interactions of clinical significance
37. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson's disease
38. The effects of cisapride on L-dopa levels and clinical response in Parkinson's disease
39. The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa
40. Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating Parkinsonian patients
41. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease
42. Pathogenetic studies of motor fluctuations in Parkinson's disease
43. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism
44. The effects of oral protein on the absorption of intraduodenal levodopa and motor performance
45. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa
46. Protein redistribution diet remains effective in patients with fluctuating parkinsonism
47. L-dopa Pharmacokinetics in plasma and cistemal and lumbar cerebrospinal fluid of monkeys
48. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease
49. Catecholamines in CSF, plasma and, tissue after autologous transplantation of adrenal medulla to the brain in patients with Parkinson's disease
50. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease
51. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration
52. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism of blood plasma and skeletal muscle in beagle dog: An in vivo microdialysis study
53. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order
54. Diurnal differences in response to oral levodopa
55. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease
56. Age influences magnitude but not duration of response to levodopa
57. Concentration-effect relationship of levodopa in patients with Parkinson's disease
58. Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: A 3-year follow-up study
59. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients
60. A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease
61. Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations
62. Long-duration response to levodopa influences the pharmacodynamics of short duration response in Parkinson's disease
63. Pharmacodynamics of the long-duration response to levodopa in PD
64. The long-duration action of levodopa may be due to a postsynaptic effect
65. L-dopa: How it may exacerbate parkinsonian symptoms
66. Pathogenesis of dyskinesias in Parkinson's disease
67. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products
68. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations
69. The promise and limitations of controlled-release oral levodopa administration
70. Controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with response fluctuations on standard levodopa treatment: Clinical and pharmacokinetic observations
71. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa
72. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients
73. Immediate-release and controlled-release carbidiopa/levodopa in PD: A 5-year randomized multicenter study
74. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-relase formulation of levodopa and benserazide in healthy subjects
75. Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions
76. Levodopa infusion therapy
77. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa
78. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations
79. Clinical pharmacokinetics of ropinirole
80. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
81. Levodopa toxicity and apoptosis
82. Levodopa: Is toxicity a myth?
83. 'Early' initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease
84. Long-term follow-up of early dopa treatment in Parkinson's disease
85. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease
86. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon 'off' periods in Parkinson's disease
87. Levodopa ethylester: A novel rescue therapy for response fluctuations in Parkinson's disease
88. Structure and function of dopamine receptors
89. Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats
90. Pathophysiology of L-dopa-induced dyskinesias
91. Clinical pharmacology of dopamine agonists in Parkinson's disease
92. Neuroprotection by dopamine agonists
93. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist
94. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity
95. Apomorphine protects against MPTP-induced neurotoxicity in mice
96. Peripheral pharmacokinetics of apomorphine in humans
97. Absorption of apomorphine by various routes in parkinsonism
98. Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease
99. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers
100. Disposition of oral lisuride in Parkinson's disease
101. Pergolide: A review of its pharmacological properties and therapeutic potential in Parkinson's disease
102. Parkinson's disease: Pathological mechanisms and actions of piribedil
103. Pramipexole: A new dopamine agonist for the treatment of Parkinson's disease
104. Sensitive, specific radioimmunoassay for quantifying pergolide in plasma
105. Triple stage quadrupole mass spectrometric determination of bromocriptine in human plasma with negative ion chemical ionization
106. High-performance liquid chromatographic assay of bromocriptine in rat plasma and brain
107. Quantitative determination of the dopamine agonist lisuride in plasma using high-performance liquid chromatography with fluorescence detection
108. Application of thermospray liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry for the identification of cynomolgus monkey and human metabolites of SK & F 101468, a dopamine D2 receptor agonist
109. Determination of pramipexole (U-98,528) in human plasma and urine by high-performance liquid chromatography with electrochemical and ultraviolet detection
110. Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection
111. Determination of piribedil and its basic metabolites in plasma by high-performance liquid chromatography
112. Transfer of bromocriptine across the blood-brain barrier in man
113. Bromocriptine in Parkinson's disease
114. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinsons disease: Three year interim report
115. The Sydney Multicentre Study of Parkinson's disease: A randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa
116. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five year follow up
117. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease
118. Drug therapy: Bromocriptine
119. Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy
120. Alcohol increases bromocriptine's side effects
121. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen
122. Physiologic disposition of pergolide
123. Pergolide monotherapy in the treatment of early PD: A randomized, controlled study
124. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients
125. Dopamine agonists in Parkinson's disease
126. Lisuride, a dopamine agonists in the treatment of early Parkinson's disease
127. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
128. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
129. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial
130. Efficacy of pirihedil in adjunction to L-dopa in a six-month randomized placebo controlled study in early Parkinson's disease
131. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
132. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease
133. Lisuride combined with levodopa in advanced Parkinson disease
134. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study
135. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
136. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
137. Long-term study of pergolide in Parkinson's disease
138. Pergolide mesylate: Four years experience in Parkinson's disease
139. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease
140. Comparison of pergolide and bromocriptine therapy in parkinsonism
141. Chronic agonist therapy for Parkinson's disease: A 5-year study of bromocriptine and pergolide
142. Agonist substitution in advanced Parkinson's disease
143. Double-blind assessment of potential pergolide-induced cardiotoxicity
144. Pergolide-induced hypotension
145. Antiparkinsonian dopamine agonists: A review of the pharmacokinetics and neuropharmacology in animals and humans
146. Lisuride infusion pump: A device for the treatment of motor fluctuations in Parkinson's disease
147. Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease
148. Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: Effect on plasma prolactin level
149. Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations: Long-term study over 10 years in comparison with L-dopa monotherapy
150. Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease
151. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease
152. Pergolide and lisuride in advanced Parkinson's disease
153. Subcutaneous lisuride infusion in Parkinson's disease: Response to chronic administration in 34 patients
154. Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson's disease
155. Dopamine agonists in Parkinson's disease: A look at apomorphine
156. Apomorphine and parkinsonism
157. On-off fluctuations in Parkinson's disease: A clinical and neuropharmacological study
158. Intranasal apomorphine: A new treatment in Parkinson's disease
159. Sublingual apomorphine and Parkinson's disease
160. Subcutaneous apomorphine in the treatment of Parkinson's disease
161. Subcutaneous apomorphine in Parkinson's disease
162. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years
163. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment
164. Pen injected apomorphine against off phenomena in late Parkinson's disease: A double blind, placebo controlled study
165. A pharmacokinetic interaction between subcutaneous apomorphine and levodopa/carbidopa (Sinemet)
166. Effect of tolcapone on plasma and striatal apomorphine disposition in rats
167. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease
168. Single dose response to pramipexole in patients with Parkinson's disease
169. Pramipexole: A review of its use in the management of early and advanced Parkinson's disease
170. Safety and efficacy of pramipexole in early Parkinson's disease: A randomized dose-ranging study
171. Pramipexole vs levodopa as initial treatment for Parkinson's disease: A randomized controlled trial
172. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study
173. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
174. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist
175. Ropinirole: A review of its use in the management of Parkinson's disease
176. Ropinirole for the treatment of early Parkinson's disease
177. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease
178. Pharmacodynamic and pharmacokinetic features of cabergoline: Rationale for use in Parkinson's disease
179. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa
180. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease
181. Piribedil induces low levels of dyskinesia in MPTP-treated common marmosets
182. Preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agent
183. Piribedil therapy in Parkinson's disease: Use of the drug in the retard form
184. Activity and acceptability of piribedil in Parkinson's disease: A multicentre study
185. Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET)
186. Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus
187. A study of the N-methyl-D-aspartate antagonistic properties of anticholinergic drugs
188. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: Binding and patch clamp studies
189. Development of a sensitive and specific radioimmunoassay for benztropine
190. Biperiden effects and plasma levels in volunteers
191. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects
192. The bioavailability of orphenadrine hydrochloride after intramuscular and oral administration
193. Pharmacokinetics and pharmacodynamics of procyclidine in man
194. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients
195. Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans
196. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone
197. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease
198. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease
199. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies
200. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects
201. Clinical pharmacokinetics and pharmacodynamics of selegiline: An update
202. Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids
203. Stereoselective determination of trihexyphenidyl in human serum by LC-ESI-MS
204. Metabolism and urinary excretion of benzhexol in humans
205. Five year follow-up of treatment with trihexyphenidyl (Artane®)
206. The effect of trihexyphenidyl, an anticholinergic agent, on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease
207. Comparison of central and peripheral pharmacologic effects of biperiden and trihexyphenidyl in human volunteers
208. Intrastriatal dialysis evidence for a direct inhibitory effect of benztropine on dopamine reuptake
209. High-performance liquid chromatographic method for the analysis of benztropine in human plasma
210. Phase I and II metabolites of benztropine in rat urine and bile
211. In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity
212. Simple and rapid GLC method for the determination of orphenadrine in human plasma
213. Screening procedure for the detection of alkanolamine antihistamines and their metabolites in urine using computerized gas chromatography-mass spectrometry
214. Determination of diphenylmethane antihistaminic drugs and their analogues in body fluids by gas chromatography with surface ionization detection
215. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes
216. Metabolic studies of 3H-orphenadrine citrate in the rat, dog and rhesus monkey
217. Analysis of procyclidine in human plasma and urine by gas-liquid chromatography
218. Microbore liquid chromatography of tertiary amine anticholinergic pharmaceuticals with tris(2,2′-bipyridine)ruthenium(III) chemiluminescence detection
219. Metabolism of procyclidine in isolated rat hepatocytes
220. Capillary gas chromatographic determination of biperiden in human plasma
221. A simple but highly sensitive radioreceptor assay for the determination of scopolamine and biperiden in human plasma
222. Pharmacokinetic-dynamic study on different oral biperiden formulations in volunteers
223. Muscarinic receptor occupancy by biperiden in living human brain
224. Sebum secretion in idiopathic Parkinson's disease: Effect of anticholinergic and dopaminergic drugs
225. Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges
226. The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers
227. Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease: Effect on levodopa bioavailability
228. Amantadine in the treatment of Parkinson's disease
229. Amantadine in Parkinson's disease
230. The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way
231. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine
232. Direct determination of adamantanamine in plasma and urine with automated solid phase derivatization
233. Amantadine and motor fluctuations in chronic Parkinson's disease
234. Treatment of Parkinson's disease with amantadine and levodopa: A one-year study
235. Amantadine in Parkinson's disease: Pro and contra
236. The comparative value of amantadine and levodopa
237. Treatment of Parkinsonism with amantadine and levodopa
238. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease
239. Amantadine for levodopa-induced dyskinesias: A 1-year follow-up study
240. Amantadine-induced peripheral neuropathy
241. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone
242. Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons
243. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
244. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
245. Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients
246. Tolcapone improves motor function in parkinsonian patients with the 'wearing-off' phenomenon: A double-blind, placebo-controlled, multicenter trial
247. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine
248. Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection
249. Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine
250. Catechol-O-methyltransferase: Variation in enzyme activity and inhibition by entacapone and tolcapone
251. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease
252. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans
253. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers
254. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
255. Entacapone enhances the pharmacokinetic and clinical response of levodopa when administered with Sinemet depot
256. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone
257. Positron emission tomography in drug evaluation: Influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey
258. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects
259. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites
260. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation
261. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: Correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement
262. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa
263. Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
264. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa
265. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial
266. Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study
267. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients
268. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
269. Tolcapone and fulminant hepatitis
270. Tolcapone and hepatotoxic effects
271. Hepatic safety of the COMT inhibitor entacapone
272. Comparison between the effects of L-dopa + entacapone and L-dopa + placebo on exercise capacity, haemodynamics and autonomic function in patients with Parkinson's disease
273. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise
274. COMT inhibition in Parkinson's disease: Rationale and clinical relevance
275. Endogenous dopamine-derived neurotoxins and Parkinson's disease
276. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet)
277. The effect of tolcapone on the pharmacokinetics of benserazide
278. Current status of selegiline as a neuroprotective agent in Parkinson's disease
279. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects
280. Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
281. Sensitive high-performance liquid chromatographic method for the determination of the three main metabolites of selegiline (L-deprenyl) in human plasma
282. Determination of the amine metabolites of selegiline in biological fluids by capillary gas chromatography
283. Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry
284. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding
285. Slow recovery of human brain MAO B after L-deprenyl (selegiline) withdrawal
286. Effect of deprenyl on the progression of disability in early Parkinson's disease
287. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease
288. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
289. The effect of deprenyl and levodopa on the progression of Parkinson's disease
290. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
291. Selegiline delays the onset of disability in de novo parkinsonian patients
292. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa
293. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa
294. Does selegiline delay the progression of Parkinson's disease: A critical re-evaluation of the DATATOP study
295. Nigral degeneration in Parkinson's disease in relation to clinical features
296. Effect of selegiline on mortality in patients with Parkinson's disease: A meta-analysis
297. Selegiline and mortality in subjects with Parkinson's disease: A longitudinal community study
298. Selegiline: A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease
299. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy
300. Sleep attacks and Parkinson's disease treatment
301. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: A meta-analysis of randomised controlled trials